Eurofins Scientific SE · EURONEXT:ERF

Eurofins Scientific — Debt Investor Presentation (September 2019)

41 slides from Eurofins Scientific's debt investor presentation, September 2019

  1. Slide 1: Eurofins Credit Presentation

    Eurofins A global scientific leader in bioanalytical testing in the food, environment, pharmaceutical, agrosciences, cosmetics products testing and clinical sectors Consistently delivering strong, sustainable, profitable growth Doubled revenues more than 3 times (every 4 years on average) between 20

  2. Slide 2: Disclaimer

    Disclaimer The statements made during this presentation or as response to questions during the Question & Answers period that are not historical facts are forward looking statements. Furthermore, estimates and judgements may be made based on market and competitive information available at a certain

  3. Slide 3: Contents

    Contents  Eurofins at a glance  Market & Strategic Positioning  Finance & Outlook  Contemplated transaction  Appendix 3

  4. Slide 4: Eurofins' Mission is to contribute to global Health, Safety & Environment

    Eurofins’ Mission is to contribute to global Health, Safety & Environment with the best in bioanalysis Eurofins provides testing  Founded in 1987 services in four main areas  IPO in 1997 in Paris at € 1.83 per share (vs. € 389.00 at 28/06/2019) that have a strong impact on  About 45,000 employees

  5. Slide 5: Leading global and local market positions in attractive high-growth markets (1/2)

    Leading global and local market positions in attractive high-growth markets* (1/2)… Testing for Food & Feed Environment Clinical Pharma/Biotech/Agrosciences Testing Testing Diagnostics N°1 to N°3* N°1* N°1* Start-Up Eurofins position worldwide worldwide worldwide Start 2014 Start 2000-2005 Start 198

  6. Slide 6: Leading global and local market positions in attractive high-growth markets (2/2)

    Leading global and local market positions in attractive high-growth markets* (2/2) Testing for Food & Feed Environment Clinical Pharma/Biotech/Agrosciences Testing Testing Diagnostics N°1 to N°3* N°1* N°1* Start-Up Eurofins position worldwide worldwide worldwide Start 2014 Start 2000-2005 Start 1987

  7. Slide 7: Global leadership positions in 5 high potential niche markets

    Eurofins has also established global leadership positions in 5 high potential niche markets Agroscience CRO** Cosmetics Advanced Materials Genomic Services Discovery Pharmacology Services Testing Sciences N°2* Worldwide N°1* N°1* N°1* N°1* Eurofins N°1* worldwide worldwide worldwide worldwide positi

  8. Slide 8: In 2018, Eurofins reached new number 1 leadership positions in the U.S. and Europe

    In 2018, Eurofins reached new number 1 leadership positions in the U.S. and Europe thanks to organic growth, strategic acquisitions and start-up laboratories Eurofins has achieved new leadership positions in Food, Environment and Biopharma Product testing:  U.S. – market leader in Food testing – ac

  9. Slide 9: Upwards revision of objectives to double revenues; €5bn in 2020

    Upwards revision of objectives to once again double revenues in only 3 years (between 2015 and 2018) instead of 5, and reach €5bn in 2020 vs €4bn originally planned in 2015 for 2020 Illustration of Eurofins’ 2019-2020 growth objectives assuming constant/linear acquisition volume and growth rate each

  10. Slide 10: Cyber Attack Update

    Cyber Attack Update • All operations and systems have been restored • The investigations conducted so far by our internal and external IT forensics experts have concluded that there should be no significant residual risk from the ransomware attack and have not found evidence of any unauthorised thef

  11. Slide 11: Contents

    Contents  Eurofins at a glance  Market & Strategic Positioning  Finance & Outlook  Contemplated transaction  Appendix 11

  12. Slide 12: Drivers for high long-term above GDP market growth

    Drivers for high long-term above GDP market growth Secular Underlying Fundamentals General Market Drivers Laboratory Market Drivers Demand for safe Consumer Increasing wealth pharmaceuticals, quality food expectations for and clean environment and quality of Life protection Consolidation of the frag

  13. Slide 13: High barriers to entry reinforcing leadership positions

    Building leadership positions in an industry with significant network effects and competitive advantage for the market leader High level of investment and innovation required to build and efficiently run a network of modern laboratories (buildings, equipment, IT High barriers infrastructure and solu

  14. Slide 14: Eurofins is the leader in most of its markets

    Eurofins is the leader in most of its markets and continues to build global & local leadership positions* in markets where scale matters New Markets 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 Denmark: Food and Environment Testing Sweden, Norway: Fo

  15. Slide 15: We have built a hard-to-replicate world-class infrastructure

    We have built a hard-to-replicate world-class infrastructure Eurofins has been consistently investing more than its peers (average if more than 1 year) 12% 180% 160% 10% 140% 8% 120% Excess Investment Capex to Sales 100% 6% 80% 4% 60% 40% 2% 20% 0% 0% 00-'04 05-'08 09-'10 '05-'12 2010 2011 2012 2013

  16. Slide 16: Strategy aims at building long lasting competitive advantage

    Eurofins’ strategy aims at building long lasting competitive advantage in very attractive markets Leading technology Quality of customer service  Competence Centres & R&D activities  Extensive expertise in local regulations for all major markets, and one-stop contact for  Proprietary technologies

  17. Slide 17: Contents

    Contents  Eurofins at a glance  Market & Strategic Positioning  Finance & Outlook  Contemplated transaction  Appendix 17

  18. Slide 18: Positive trends drive solid operating results

    Positive trends drive solid operating results H1 2019 (including IFRS 16) H1 2018 +/- % +/- % In €m except otherwise stated Adjusted1 Separately Statutory Adjusted Separately Statutory Adjusted Reported Results* disclosed Results Results disclosed Results Results Results items2 items Revenues 2,167.

  19. Slide 19: Robust financial performance in H1 2019 despite cyber-attack

    Eurofins reports robust financial performance in H1 2019 despite disruptions from the June cyber-attack Eurofins 3 year Report Card: H1 2016 – H1 2019 CAGR** H1 2019 Results Highlights  24% revenue growth to EUR 2,168m  Organic growth* in the period January to May 2019 was over 4.5% (5.5% 22% excl

  20. Slide 20: Solid Balance Sheet

    Solid Balance Sheet Hybrid  €300m hybrid issued in Jan 2013/Jul 2014, callable at par by June 2019 June 2019 Dec 2018 Eurofins in Jan 2020. Bears a fixed coupon of 7.00% until first Post IFRS 16* Pre. IFRS 16* call, Euribor 3m + 818 bp thereafter if not called  Net Debt/ L12M Adjusted  €300m hybr

  21. Slide 21: Majority of debt instruments bear low fixed interest rates for long maturities

    The majority of Eurofins’ debt instruments bear low fixed interest rates for long maturities Bond, Schuldschein & Hybrid Capital Maturity Profile Over the years, strict financial discipline has allowed Eurofins to significantly reduce its average cost of funding by refinancing older more expensive d

  22. Slide 22: Midterm objective to reach 20% adjusted EBITDA margin

    Midterm objective to reach 20% adjusted EBITDA margin, and strengthen cash flow generation Eurofins Cashflow Expansion Levers In spite of 20 start-ups per year (average past 5 Objectives*: years) Separately Disclosed Items (SDI) costs • Self-imposed limits of €300m each should reduce as % of Adjuste

  23. Slide 23: Outlook: becoming the world leader in bioanalytical testing

    Outlook: becoming the world leader in the bioanalytical testing market Sustainable Market Growth Drivers + Key Success Factors = Solid Outlook*  Food safety & contamination  Unique technological portfolio of 2019 Objectives issues over 200,000 methods  €4.5bn Revenues  €850m Adjusted EBITDA  Ne

  24. Slide 24: Conclusion: our sustainable competitive advantage

    Conclusion: our sustainable competitive advantage Best in class technology and quality give best brand High-growth, non-cyclical markets driven by secular protection mega-trends N° 1 or 2 worldwide in most business lines Advancing globalisation but with very few global Network in 47 countries testin

  25. Slide 25: Contents

    Contents  Eurofins at a glance  Market & Strategic Positioning  Finance & Outlook  Contemplated transaction  Appendix 25

  26. Slide 26: Issuance rationale

    Issuance rationale Use of proceeds:  General corporate purpose, including the refinancing of the “PerpNC2020” notably through the concomitant any and all tender offer launched on those PerpNC2020 No liquidity issue:  305M€ of cash on balance sheet at end of June 2019; 750M€ Commercial Paper progra

  27. Slide 27: New Hybrid - Key Terms & Conditions

    New Hybrid - Key Terms & Conditions Classical unrated structure NEW HYBRID - KEY TERMS AND CONDITIONS Issuer: Eurofins Scientific S.E. Offering: Undated 3-Year Non-Call Deeply Subordinated Fixed to Floating Rate Bonds (the "Bonds") Issue rating: Unrated (a rating may be assigned at a later date) Iss

  28. Slide 28: Calendar

    Calendar INDICATIVE TRANSACTION TIMETABLE AND CALENDAR Launch of the Tender Offer 3 September 2019 September 2019 Pricing of the New Bonds On or before the Expiration Time M T W T F 16:00 hours CET on 10 September Expiration Time 2019 2 3 4 5 6 Announcement of the results of the As soon as practicab

  29. Slide 29: Contents

    Contents  Eurofins at a glance  Market & Strategic Positioning  Finance & Outlook  Contemplated transaction  Appendix 29

  30. Slide 30: Summarized Income Statement

    Summarized Income Statement Condensed Interim Consolidated Income Statement (Unaudited) January 1, 2019 to June 30, 2019 H1 2019 H1 2018 Adjusted Separately Adjusted Separately EUR Thousands Total Total results disclosed items results disclosed items Revenues 2,167,675 - 2,167,675 1,743,315 - 1,743,

  31. Slide 31: Summarized Balance Sheet

    Summarized Balance Sheet Condensed Interim Consolidated Balance Sheet (Unaudited) As of June 30, 2019 June 30, December 31, EUR Thousands 2019 2018 Property, plant and equipment 1,492,728 1,018,005 Goodwill 3,554,922 3,418,328 Other intangible assets 971,826 946,918 Investments in associates 4,909 5

  32. Slide 32: Summarized Cash Flow Statement

    Summarized Cash Flow Statement Condensed Interim Consolidated Cash Flow Statement (Unaudited) January 1, 2019 to June 30, 2019 EUR Thousands H1 2019 H1 2018 Cash flows from operating activities Profit before income taxes 88,129 122,527 Adjustments for: Depreciation and amortisation 182,243 104,855 S

  33. Slide 33: IFRS 16 impact on Income Statement

    IFRS 16 impact on Income Statement IFRS 16 increases reported EBITDA by EUR 62 million H1 2019 H1 2019 H1 2018 IFRS 16 excluding Reported Reported impact IFRS 16 Results Results EUR Thousands Total Total Total Revenues 2,167,675 - 2,167,675 1,743,315 Operating costs, net -1,858,951 +62,188 -1,796,76

  34. Slide 34: IFRS 16 impact on Balance Sheet

    IFRS 16 impact on Balance Sheet IFRS 16 increases total assets by EUR 467 million H1 2019 H1 2019 H1 2018 EUR Thousands excluding IFRS 16 impact Reported Reported IFRS 16 Results Results Property, plant and equipment 1,039,063 +453,665 1,492,728 792,556 Goodwill 3,554,922 - 3,554,922 2,669,643 Other

  35. Slide 35: IFRS 16 impact on Cash Flow Statement

    IFRS 16 impact on Cash Flow Statement H1 2019 IFRS 16 H1 2019 H1 2018 EUR Thousands excluding Impact Reported Reported IFRS 16 Cash flows from operating activities Profit before income taxes 89,270 -1,141 88,129 122,527 Adjustments for: Depreciation and amortisation 131,458 +50,785 182,243 104,855 S

  36. Slide 36: Post acquisition, sales and profits often increase significantly

    Post acquisition and integration into Eurofins, both sales and profits often increase significantly Illustration Growth drivers post acquisition: 1) Sales increase through cross selling of Actual example of an acquired lab: Eurofins lab specialities internationally 2) Cost reduction – focus on most

  37. Slide 37: Eurofins ESG Summary

    Eurofins ESG Summary Eurofins’ Mission: To contribute to a safer and healthier world by providing its customers with innovative and high quality laboratory and advisory services whilst creating opportunities for our employees and generating sustainable shareholder value.  Eurofins‟ directly and ind

  38. Slide 38: Corporate Governance Improvements 2018

    Corporate Governance Improvements 2018  Update of Corporate Governance Charter, Code of Ethics, Anti-Bribery Policy, Modern Slavery, Human Trafficking & Child Labour Statement in line with best practice  Nomination and Remuneration Committee  Creation of the Committee  Benchmark study on CEO and

  39. Slide 39: Audit Coverage

    Audit Coverage  In 2019 newly appointed auditor Deloitte Audit FY 2018 accounts FY 2017 accounts 2018 PwC coverage accounts Tier 1 & Tier 2 PwC coverage 2017 Tier 1accounts & Tier 2 for PwC coverageauditors Tier 1 & Tier 2 for PwC coverage auditors Tier 1 & Tier 2 Consolidated coverage for Consolid

  40. Slide 40: Related Party Transactions at Arms' Length

    Related Party Transactions at Arms’ Length  Corporate Governance Committee ensures that rentals with related parties are complying with best governance practice, especially with regards to:  Non-implication from related parties in the internal decision making  Arms lengths terms and conditions, d

  41. Slide 41: ESG illustrations

    ESG illustrations Highlights from an ESG Survey* conducted by Eurofins for Highlights from the Sustainability Report 2018 by Eurofins 2018: Lancaster Laboratories (ELL), the largest independent single- site laboratory in the World in our markets with more than 1,800 employees: Environmental  Direct

Eurofins Scientific — Debt Investor Presentation (September 2019) on 6ix